Eisai, the First Japanese Pharmaceutical Firm to Open Regional Clinical Research Centre in Singapore
Eisai Co., Ltd, announced the opening of its Regional Clinical Research Centre in Singapore - Eisai Clinical Research Singapore Pte Ltd. It is the first Japanese Pharmaceutical Company to do so here, recognising Singapore's enormous growth in the biomedical sciences industry over the last few years, primarily because of its stable and pro-business government, which has offered policies that attract much foreign direct investment in this industry.
Eisai's research and development strategy is to focus on integrative neuroscience and integrative oncology-related products. With the company's growth progression, Eisai Global Clinical Development, the company's global unit for clinical development, was organised to centralise the management of global clinical development. In order to respond to the recent clinical research growth of Asia, Oceania, and the Middle East (AOME), Eisai Global Clinical Development proposed the establishment of the Eisai Clinical Research Singapore Pte Ltd., seeking productivity and efficiency in clinical development in the region.
At the opening ceremony held at new office location in Gateway East, Eisai Clinical Research Singapore has taken the initial steps to strategically grow its clinical research operations in the region in order to achieve greater efficiency in bringing more new products into the region and global market. This will be in line with the Eisai's human health care (hhc) philosophy to fulfill the unmet medical needs and increase benefits to the patients and their families. In an earlier opening ceremony dinner last night, Mr. Philip Yeo, Chairman, SPRING Singapore, and Ms. Aw Kah Peng, Assistant Managing Director, Economic Development Board, graced the event.
Other news from the department business & finance
